Floatz logo

Pembrolizumab

Rhabdoid Tumor

Seattle Children's Hospitalmonoclonal_antibodyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

33 Active assets in the Rhabdoid Tumor cohort.

Asset / SponsorPhaseRating
Tazemetostat
Epizyme, Inc.
Phase 2BB
Hycamtin
Pfizer
Phase 2B
Cyclophosphamide
St. Jude Children's Research Hospital
Phase 2B
Olaparib
National Cancer Institute (NCI)
Phase 2B
PI3K/MTOR INHIBITOR LY3023414
National Cancer Institute (NCI)
Phase 2B

View all 44 →

Same molecule, other indications

Pembrolizumab is also rated in:

Her2-receptor negative breast cancerDormant
BBB
Indicative ·
72 / 100
View asset →
estrogen-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →
progesterone-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →